Contact
Diario Médico explains the research line followed by the lab led by Ernest Giralt, head of the Chemistry and Molecular Pharmacology Programme at IRB Barcelona, on a peptide that inhibits aggregation of the beta amyloid protein, a characteristic of Alzheimer’s disease. Giralt has presented the results of his study in the Barcelona BioMed Conference entitle “Engineering peptides”, organized by IRB Barcelona and the BBVA Foundation.
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
